Currently out of the existing stock ratings of Justin Kim, 56 are a BUY (88.89%), 7 are a HOLD (11.11%).

Justin Kim

Work Performance Price Targets & Ratings Chart

Analyst Justin Kim, currently employed at OPPENHEIMER, carries an average stock price target met ratio of 65.56% that have a potential upside of 67.51% achieved within 301 days.

Justin Kim’s has documented 121 price targets and ratings displayed on 12 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on CYTK, Cytokinetics at 27-Feb-2025.

Wall Street Analyst Justin Kim

Analyst best performing recommendations are on AUPH (AURINIA PHARMACEUTICALS).
The best stock recommendation documented was for AUPH (AURINIA PHARMACEUTICALS) at 10/28/2021. The price target of $32 was fulfilled within 1 day with a profit of $2.04 (6.81%) receiving and performance score of 68.09.

Average potential price target upside

of $20.85 (65.25%) on ANGN (ANGION BIOMEDICA CORP).
of $19.27 (50.84%) on APLS (APELLIS PHARMACEUTICALS).
of $17.09 (35.38%) on CYTK (CYTOKINETICS).

ANGN Angion Biomedica Corp APLS Apellis Pharmaceuticals AUPH Aurinia Pharmaceuticals BCRX BioCryst Pharmaceuticals CYTK Cytokinetics PRVB Provention Bio PHVS Pharvaris BV ALDX Aldeyra The IMCR Immunocore Holdings Ltd KDNY Chinook Therapeutics IONS Ionis Pharmaceuticals ALPN Alpine Immune Sciences

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Raghuram Selvaraju (HC WAINWRIGHT)